2021
DOI: 10.1007/5584_2021_625
|View full text |Cite
|
Sign up to set email alerts
|

Cartilage Repair by Mesenchymal Stem Cell-Derived Exosomes: Preclinical and Clinical Trial Update and Perspectives

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 147 publications
0
11
0
Order By: Relevance
“…When transplanted in vivo into specific organs, ADSCs demonstrate a high regenerative potential and impart to specific cell formation and to the repletion of the blood vessels probably due to their intrinsic multipotency [ 31 , 32 ]. Mesenchymal cells of human adult tissue can be directed toward an organ-specific cell phenotype when in contact with differentiating primary organ progenitor cells in vitro and in vivo [ 32 , 33 , 34 ], whereas ADSCs are likely unable to produce new muscle fibers de novo or even to promote a complete skeletal muscle program [ 35 , 36 ]. In this context, ADSC-based therapy may contribute to the further development of tissue engineering to recover tissue defects or damage after oncologic surgery leading to cosmetic problems [ 37 ].…”
Section: Discussionmentioning
confidence: 99%
“…When transplanted in vivo into specific organs, ADSCs demonstrate a high regenerative potential and impart to specific cell formation and to the repletion of the blood vessels probably due to their intrinsic multipotency [ 31 , 32 ]. Mesenchymal cells of human adult tissue can be directed toward an organ-specific cell phenotype when in contact with differentiating primary organ progenitor cells in vitro and in vivo [ 32 , 33 , 34 ], whereas ADSCs are likely unable to produce new muscle fibers de novo or even to promote a complete skeletal muscle program [ 35 , 36 ]. In this context, ADSC-based therapy may contribute to the further development of tissue engineering to recover tissue defects or damage after oncologic surgery leading to cosmetic problems [ 37 ].…”
Section: Discussionmentioning
confidence: 99%
“…EV transfer of miRNA has been extensively researched during the past decade. In particular, MSCs isolated from diverse sources (bone marrow, synovial membrane, adipose tissue, umbilical cord and embryonic cells) were reported to be able to transduce miRNA effects through secretion of EVs [37][38][39], mainly through leading to immunomodulation. Here, we demonstrated that chondrocytes also secrete miRNA through EVs and that the content of the EVs can be controlled by the expression of the miRNA.…”
Section: Discussionmentioning
confidence: 99%
“…As a cell-free therapeutic method, many studies have reported the protective or destructive role of EVs by affecting cartilage repair, 39 synovialis, 40 and subchondral bone remodeling 41 in the progress of OA and raised considerable interests in the scientific research field. Although most cells could secret EVs, most studies preferred to utilize different mesenchymal stem cells (MSCs) as the source of EVs due to the particular function such as differentiation, regeneration, and anti-inflammation of MSCs in the treatment of OA.…”
Section: The Application Of Evs-mirnas In Oa Treatmentmentioning
confidence: 99%